Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Trading Down 5.2%

EVGN opened at $1.27 on Wednesday. The business’s 50 day moving average is $1.19 and its 200-day moving average is $1.45. The stock has a market cap of $6.81 million, a PE ratio of -0.28 and a beta of 1.55. Evogene has a twelve month low of $0.95 and a twelve month high of $9.00.

Evogene (NASDAQ:EVGN) last posted its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. During the same period last year, the firm earned ($1.30) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EVGN. Citadel Advisors LLC bought a new stake in Evogene during the fourth quarter worth approximately $30,000. Jane Street Group LLC acquired a new position in shares of Evogene during the 4th quarter valued at $40,000. Finally, Armistice Capital LLC increased its position in shares of Evogene by 5.9% during the 1st quarter. Armistice Capital LLC now owns 316,024 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 17,743 shares during the period. 10.40% of the stock is currently owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.